Australian tertiary care outcomes of entecavir monotherapy in treatment naive patients with chronic hepatitis B

作     者：Farzan Fahrtash-Bahin Viraj C Kariyawasam Timothy Gray Karen Byth Jacob George Mark W Douglas 

作者机构：Storr Liver UnitWestmead Millennium InstituteUniversity of Sydney at Westmead Hospital2145 SydneyAustralia Centre for Infectious Diseases and Microbiology and Sydney Emerging Infections and Biosecurity InstituteUniversity of Sydney at Westmead Hospital2145 SydneyAustralia Department of BiostatisticsSchool of Public HealthUniversity of Sydney2145 SydneyAustralia 

出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)

年 卷 期：2013年第19卷第5期

页      面：721-726页

核心收录：

学科分类：1004[医学-公共卫生与预防医学(可授医学、理学学位)] 100401[医学-流行病与卫生统计学] 10[医学] 

主　　题：Chronic hepatitis B Entecavir Australia Asia-Pacific Monotherapy Hepatitis B virus Antivirals 

摘      要：AIM:To evaluate the long-term treatment outcomes of entecavir monotherapy in treatment naive patients in an Australian tertiary care setting. METHODS:A retrospective analysis of treatment naive patients receiving entecavir monotherapy through Westmead Hospital was *** were excluded if they had received previous treatment with another nucleoside or nucleotide analogue,were pregnant or less than 18 years old. RESULTS:Out of 336 patients,163 patients fulfilled the selection *** of follow up was 3-46 mo (mean 26 mo).134 patients(82.2%)had pre-treatment biopsies,with 26 patients(16.0%)demonstrating F3-4 *** total,153 patients(93.9%)achieved at least Partial Virological Suppression(PVS),with 134 patients (82.2%)achieving complete virological suppression. The cumulative CVS and PVS rates at 36 mo were 82.1%and 96.4%,respectively.3 patients(1.8%)failed to achieve PVS,while 5 patients(3.0%)developed virological rebound.128 patients(78.5%)maintained CVS throughout follow *** of CVS included lower baseline DNA level(P=0.001),hepatitis B virus e antigen negative status(P=0.001)and increasing age at treatment(log rank 0.001).No significant adverse effects were reported necessitating cessation of entecavir. CONCLUSION:Entecavir monotherapy is efficacious and safe in an Australian tertiary care *** and rebound rates are very *** is similar to data from controlled and uncontrolled trials around the world.